Ladenburg, Germany, 29 November 2023 – Heidelberg Pharma AG (FSE: HPHA) today announced that Dr. Jan Schmidt-Brand, Chief Executive Officer (CEO) of Heidelberg Pharma AG and Managing Director of the subsidiary Heidelberg Pharma Research GmbH, is planning to retire at the beginning of February 2024 and step down from his positions. The Supervisory Board has appointed Prof. Dr. Andreas Pahl as CEO effective 1st February 2024. Mr. Pahl will also assume the role of Managing Director of the subsidiary.
Prof. Pahl has been Head of Research & Development at Heidelberg Pharma since 2012 and has been a member of the Executive Board since 2016. He holds a doctorate in chemistry and previously worked in the pharmaceutical industry and in academic research and teaching for over 25 years.
Dr. Schmidt-Brand has been with Heidelberg Pharma since 2001, first as Managing Director of the subsidiary Heidelberg Pharma Research GmbH and since 2012 as a member of the Management Board of Heidelberg Pharma AG. He will continue to support the company as a consultant.
+++ End of the ad hoc announcement +++
